Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 3Completed 2Withdrawn 1Unknown 1Terminated 1Active not recruiting 1

Sponsor Class

NIH 2OTHER 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 299Neoplasms 179Breast Neoplasms 172Colorectal Neoplasms 107Neoplasm Metastasis 101Melanoma 99Multiple Myeloma 91Prostatic Neoplasms 90Ovarian Neoplasms 83Recurrence 79Carcinoma, Renal Cell 73Lung Neoplasms 71Stomach Neoplasms 67Squamous Cell Carcinoma of Head and Neck 67Lymphoma, Non-Hodgkin 60Pancreatic Neoplasms 59Leukemia, Lymphocytic, Chronic, B-Cell 56Leukemia, Myeloid, Acute 54Carcinoma, Hepatocellular 48Triple Negative Breast Neoplasms 47Small Cell Lung Carcinoma 46Urinary Bladder Neoplasms 45Lymphoma, Large B-Cell, Diffuse 43Head and Neck Neoplasms 41Endometrial Neoplasms 41Lymphoma, Follicular 39Lymphoma 37Uterine Cervical Neoplasms 35Parkinson Disease 4, Autosomal Dominant Lewy Body 35Glioblastoma 34

Interventions

belzutifan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × INDUSTRY × von Hippel-Lindau Disease × Clear all
NCT03401788 2026-04-13

MK-6482-004

Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 2 Active not recruiting
50 enrolled 1 FDA

von Hippel-Lindau Disease

Data powered by HemOnc (CC BY 4.0) Colophon âš¡